Toronto - Delayed Quote CAD

Cardiol Therapeutics Inc. (CRDL.TO)

2.4500 -0.0500 (-2.00%)
At close: April 26 at 3:59 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CRDL.TO

Recent News: CRDL.TO

View More
Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Cardiol Therapeutics Announces Year-End 2023 Update on Operations
Newsfile 25 days ago
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Newsfile 2 months ago
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Newsfile 2 months ago
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
Newsfile 3 months ago
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Newsfile 3 months ago
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
Newsfile 4 months ago
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Newsfile 5 months ago
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Newsfile 5 months ago

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Newsfile 6 months ago
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
News Direct 6 months ago
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol

Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol
News Direct 6 months ago
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
Newsfile 6 months ago
View More

Related Tickers

MDP.TO Medexus Pharmaceuticals Inc.
1.9200
+3.23%
 
2HQ.F Tilray Brands, Inc.
1.6950
+2.73%
 
CPH.TO Cipher Pharmaceuticals Inc.
8.50
0.00%
 
CURA.TO Curaleaf Holdings, Inc.
6.78
+4.47%
 
CL.CN Cresco Labs Inc.
2.8200
+6.02%
 
CRON.TO Cronos Group Inc.
3.5300
+2.62%
 
AYR-A.CN Ayr Wellness Inc.
3.2500
+3.83%
 
VPH.TO Valeo Pharma Inc.
0.1150
+21.05%
 
0ET.SG Esperion Therapeutics Inc
1.8105
-0.17%
 
BHC.TO Bausch Health Companies Inc.
11.92
+1.10%